Brief: Resverlogix Gets Positive DSMB Recommendation For Phase 3 Study Of Apabetalone
27/03/2019 20:33
March 27 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES NINTH POSITIVE DATA SAFETY
MONITORING
BOARD RECOMMENDATION FOR PHASE 3 STUDY OF APABETALONE
* RESVERLOGIX CORP - DSMB REVIEWED AVAILABLE SAFETY DATA AND
COMMENTED THAT NO SAFETY CONCERNS WERE IDENTIFIED
* RESVERLOGIX CORP - BETONMACE TRIAL IS CURRENTLY EXPECTED
TO BE
COMPLETED WITHIN FIRST HALF OF CALENDAR 2019
Source text for Eikon: ID:nGNX8tqtGS
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment